BeiGene li­cens­es CDK2 in­hibitor from En­sem in po­ten­tial $1.33B deal

BeiGene has struck a deal with En­sem Ther­a­peu­tics to li­cense an oral cy­clin-de­pen­dent ki­nase 2 (CDK2) in­hibitor in ex­change for an undis­closed up­front pay­ment and up to $1.33 bil­lion in mile­stones, the com­pa­nies an­nounced Tues­day.

En­sem will al­so get tiered roy­al­ties for hand­ing over the ex­clu­sive glob­al li­cense to the drug, which the com­pa­nies said is “In­ves­ti­ga­tion­al New Drug (IND) ap­pli­ca­tion-ready” and En­sem’s most ad­vanced can­di­date. While they didn’t name the pro­gram in the press re­lease, En­sem’s web­site iden­ti­fies the BeiGene-part­nered pro­gram as ETX-197.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER